Meeting
2023 ASCO Annual Meeting
Breast cancer staging for patients with “low risk” disease: Are they all the same?
Authors
Jennifer Kay Plichta
Department of Surgery, Duke University Medical Center, Durham, NC
Jennifer Kay Plichta , Samantha M. Thomas , Sydney Record , Astrid Botty van den Bruele , Akiko Chiba , Gayle DiLalla , Maggie DiNome , Laura Horst Rosenberger , Hannah Woriax , Eun-Sil Shelley Hwang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6584)
DOI
10.1200/JCO.2023.41.16_suppl.6584
Abstract #
6584
Poster Bd #
76
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
First Author: Rinath Jeselsohn
Poster
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
First Author: Marcela Carausu
Poster
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
First Author: Matthew Loft
Poster
2019 ASCO Annual Meeting
Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.
First Author: Abby Statler